Hearing Technology · Ranked #5 on our Top 10 (weighting-sensitive)
For people with severe hearing loss, implantation often genuinely reduces the tinnitus sound itself — one of the few things that does. Outside research studies, it is never done for tinnitus alone.
Evidence strength: Moderate (3/5) · Tier 2 — promising · Evidence independence: Primarily independent.
A surgically implanted electrode array that bypasses damaged hair cells and stimulates the auditory nerve directly. Tinnitus reduction is a frequent side benefit of implantation for severe-to-profound hearing loss.
Percept-level ranges (Ramakers 2015, Laryngoscope): tinnitus decreases in 25–72% of implanted patients and is completely suppressed in 8–45% — while 0–25% experience worsening and ~9% develop new-onset tinnitus. The 2024 meta-analysis adds a pooled tinnitus VAS −3.1 (a mixed scale covering annoyance/loudness/awareness, not pure loudness).
Pooled within-group THI −14.0 and TQ −15.9 across 28 mostly non-randomized cohort studies (853 patients).
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
Large consistent observational literature with genuine loudness effects earns 3/5; capped because the data are non-randomized and apply only to implant candidates.
Li Y, Yang H, Niu X, Sun Y · Diagnostics · 2024 · N=853 (28 studies) · Meta-analysis of mostly prospective cohort studies
Pooled within-group improvements after implantation: THI −14.0, TQ −15.9, tinnitus VAS −3.1. Note: the pooled VAS mixes annoyance, loudness, life-effect and awareness bands — it is NOT a pure loudness scale. The percept-level ranges come from Ramakers et al. (Laryngoscope 2015): tinnitus decreases in 25–72% and is completely suppressed in 8–45% of implanted patients — while 0–25% experience worsening.
Also reported: ~9.2% new-onset tinnitus after implantation (Assouly, cited therein). All pooled changes are pre/post within-group in non-randomized cohorts.
Wendrich AW, Assouly KKS, van Heteren JAA, Peters JPM, Grolman W, Stokroos RJ, Versnel H, Smit AL · Frontiers in Neurology · 2024 · N=120 adults with single-sided deafness randomized; at the start of follow-up: 28 implanted, 25 bone conduction device, 34 CROS, 26 no treatment · Single-centre RCT: 2:3:3 allocation to cochlear implant, or to trial periods of a bone conduction device then CROS (or the reverse); after the trial periods patients chose a device or no treatment, so the non-implant comparison groups are self-selected
At 24 months the implant group improved by a median of 23 THI points, 17 TQ points and 60 VAS points from baseline (all p<0.001), already at 3 months; the bone conduction group improved on TQ and VAS; CROS and no treatment showed no significant change. Implant vs no treatment was significant on THI, TQ and VAS; implant vs the device groups was significant for VAS but not reported significant for THI or TQ.
Tinnitus was a secondary outcome in a single-centre trial; the significance threshold was Bonferroni-corrected, and missing data rose to about 20% by 24 months. This is a trial in people with single-sided deafness, not evidence for implantation in people without qualifying hearing loss.
Strong independent. Tinnitus improvement after CI reproduced across many independent centers and meta-analyses.
Safety evidence: Moderate. Surgical risks; 0–25% experience tinnitus worsening and ~9.2% develop new-onset tinnitus after implantation (Assouly, cited in the 2024 meta-analysis).
Regulatory status: FDA approved (for hearing loss). Cochlear implants are FDA-approved for qualifying hearing loss — not specifically for tinnitus. Tinnitus benefit is an evidence-supported secondary effect.
Availability: Available at implant centers for qualifying candidates; widely insurance-covered for hearing loss · Europe: Available · Cost (approx.): $30,000–100,000+ (typically covered by insurance for hearing-loss candidacy)
Tracked trials are research in progress, not recommended treatments.
From Tinnitus Claims: Fact vs. Evidence, which checks popular claims against the research. It does not change this treatment’s evidence rating.
Evidence last reviewed: 2026-09-04 · Evidence included through: 2026-09-04 · Confidence: high. Open the interactive evidence profile · How we rate evidence.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.